Dronabinol for Perioperative Analgesia
Effective perioperative pain management remains a central goal of modern surgical care, particularly in the context of minimizing opioid exposure and its associated risks. As interest grows in opioid-sparing strategies, cannabinoids have emerged as a potential adjunct in multimodal analgesia. Dronabinol, a synthetic formulation of delta-9-tetrahydrocannabinol (THC), is approved for chemotherapy-induced nausea, vomiting, and appetite stimulation and has garnered interest from researchers for analgesia in perioperative settings.
Dronabinol activates cannabinoid type 1 (CB1) receptors in the central nervous system and cannabinoid type 2 (CB2) receptors in peripheral tissues and immune cells. These receptors modulate nociceptive signaling neurotransmitter release, and inflammatory responses, providing a biologically plausible mechanism for dronabinol to deliver analgesia in the perioperative setting. Preclinical studies have demonstrated cannabinoid-mediated reductions in hyperalgesia and allodynia, supporting the rationale for clinical investigation in acute pain states.
Clinical studies evaluating dronabinol for perioperative analgesia suggest a modest opioid-sparing effect when used as part of a multimodal regimen. In surgical patients, adjunctive dronabinol has been associated with reductions in postoperative opioid consumption without significant worsening of pain scores. This effect appears most pronounced in patients with high baseline opioid requirements or those undergoing procedures associated with significant postoperative pain. These findings are particularly relevant in the current era of opioid stewardship, where even small reductions in opioid exposure may translate into meaningful reductions in adverse events and persistent use.
Beyond analgesia, dronabinol may offer additional perioperative benefits. Its antiemetic properties can be advantageous in patients prone to postoperative nausea and vomiting, potentially reducing reliance on multiple antiemetic agents. Additionally, dronabinol has been reported to improve sleep and reduce anxiety in some patients, which may indirectly contribute to improved postoperative recovery and patient satisfaction. However, these potential benefits must be weighed against known side effects, including dizziness, sedation, tachycardia, and dysphoria.
Safety considerations are an important subject in continuing research on the perioperative use of dronabinol. Psychoactive effects limit its tolerability in some patients, and interindividual variability in response is significant. Elderly patients and those with cardiovascular disease, psychiatric disorders, or sensitivity to central nervous system depressants may be at increased risk of adverse effects. Furthermore, interactions with anesthetic agents and other sedatives necessitate careful dosing and monitoring. Current evidence does not support routine use of dronabinol as a primary analgesic; rather, it should be considered an adjunct in carefully selected patients.
Despite growing interest, the evidence base for dronabinol in perioperative analgesia remains limited. Existing studies are relatively small, heterogeneous in design, and variable in dosing regimens and surgical populations. Standardized protocols regarding timing, dose, and duration of therapy have not yet been established. Larger randomized controlled trials are needed to better define efficacy, safety, and patient populations most likely to benefit.
In conclusion, dronabinol represents a promising but still investigational adjunct for perioperative analgesia within a multimodal pain management framework. Its potential opioid-sparing effects and ancillary benefits must be balanced against psychoactive side effects and limited high-quality evidence. Until further data are available, dronabinol should be used judiciously, with careful patient selection and close perioperative monitoring.
References
1. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313(24):2474-2483. DOI: 10.1001/jama.2015.6199
2. Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering, and Medicine report. Eur J Intern Med. 2018;49:7-11. DOI: 10.1016/j.ejim.2018.01.003
3. Beaulieu P. Effects of cannabinoid receptor agonists on pain modulation. Can J Anaesth. 2005;52(8):775-782. PMID: 18615144
4. Jennings JM, Angerame MR, Eschen CL, et al. Cannabinoid use in perioperative pain management: a systematic review. J Am Acad Orthop Surg. 2020;28(3):e95-e102. PMID: 33381643
5. Goel A, McGuire J, Cowles VE, et al. Perioperative dronabinol reduces opioid consumption in acute pain: a retrospective cohort study. J Opioid Manag. 2019;15(6):453-460. PMID: 32154376